# The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

> **NCT06208072** · NA · UNKNOWN · sponsor: **Hippocration General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Primary Hypertension
- Obesity

## Interventions

- **DRUG:** Irbesartan 150mg
- **DRUG:** Eplerenone 25 mg

## Key facts

- **NCT ID:** NCT06208072
- **Lead sponsor:** Hippocration General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-02-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208072, "The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06208072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*